61 results about "Oncocyte" patented technology

The present invention provides an absorbent which can remove cells present in blood including activated leukocytes such as granulocytes and monocytes, and cancer cells as well as can remove cytokines which facilitate the activation of the remaining cells, and further has no concern for pressure loss and has high configuration stability. That is, the present invention provides an absorbent which absorbs the granulocytes and the monocytes in blood, an absorbent for cancer therapy which absorbs an immunosuppressive protein and an absorbent having a bilayer structure of a net and a nonwoven fabric, having a zeta potential of −20 mV or more, as well as a blood circulation column containing any of the absorbents filled therein.

The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5′-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3′, and preferably of the general formula 5′-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3′, wherein capital letters designate an LNA nucleotide analogue selected from β-D-oxy-LNA, β-D-thio-LNA, β-D-amino-LNA and α-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo. The LNA oligonucleotides are superior to other LNA oligonucletides targeting Surviving mRNA measured by functional read outs such as apoptosis induction and proliferation inhibition, and is potent in down-regulating Survivin mRNA and protein in transfected cancer cell lines, and induce apoptosis in combination with Taxol superior compared to other LNA oligonucleotides.

This invention provides the capture antibody and the detection antibody to detect the aspergillus, the two antibody is the single clone antibody of the cross oncocyte CCTCC NO.C200731 and CCTCC NO.C200730, they can unites the glucoprotein whose molecular weight is 25-100kDa in the cell wall of the aspergillus, the reaction with the Penicillium marneffei, white oidiomycosis, smoothness oidiomycosis, tropic oidiomycosis, close smoothness oidiomycosis, Candida krusei are all negative. The antibody in this invention can make into the immunity reagent to detect the aspergillus in common use.

The invention discloses a triphenylphosphine-polyethyleneglycol 1000 vitamin E succinate (TPGS 1000-TPP) conjugated compound, and a preparation method and application thereof. The structural formula of the compound is disclosed as Formula I. The preparation method of the conjugated compound comprises the following steps: (1) reacting triphenylphosphine and 6-bromocaproic acid to obtain 5-carboxyamyltriphenylphosphonium bromide disclosed as Formula IV; and (2) carrying out esterification reaction on the 5-carboxyamyltriphenylphosphonium bromide disclosed as Formula IV and polyethyleneglycol 1000 vitamin E succinate to obtain the conjugated compound disclosed as Formula I. The invention also discloses a mitochondrion targeted taxol liposome comprising the conjugated compound. The drug effect test proves that the mitochondrion targeted taxol liposome has strong cell toxicant action in the in-vitro cell experiment and in-vivo transplantation tumor model of human lung adenocarcinoma A549 cells and drug-resistant A549 / cDDP cells thereof and can enhance the antitumor effect of taxol on drug-resistant A549 / cDDP cells.

The invention relates to a transcription mesosome Med23 subunit serving as a target for preventing or treating cancer. Specifically, the deletion of the transcription mesosome Med23 can influence the growth and tumor forming capacity of the ras-active lung cancer cell strain and obviously reduce the conversion efficiency from oncogene ras into MEF cell. Meanwhile, the expression quantity of Med23 is obviously increased in the conversion process; and the result of chip analysis shows that the deletion of Med23 influences the expression of the ras feature gene, and the Med23 acts with Elk1 to together regulate the cell cycle / cell proliferation related gene. The Med23 is remarkably highly expressed in the ras-active lung cancer cell strain and a clinical sample of lung cancer, and the expression quantity is remarkably related to prognosis; and the deletion of Med23 also can reduce the tolerance of the cancer cells to the chemotherapeutic drugs. Therefore, the Med23 is a potential cancer treatment target.

The invention aims to provide an application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma. Experiments show that the chlorogenic acid can activate CD4 T-lymphocytes and CD8 T-lymphocytes, and prevent and treat primary cutaneous T-cell lymphoma by taking the CD4 T-lymphocytes and the CD8 T-lymphocytes as targets. According to the invention, the chlorogenic acid is adopted for promoting the proliferation of T-lymphocytes of a body and activating the T-lymphocytes so as to achieve the purpose of treating primary cutaneous T-cell lymphoma. Meanwhile, the chlorogenic acid also can inhibit the proliferation of primary cutaneous T-cell lymphoma cells, and the inhibition effect of the chlorogenic acid is similar to the inhibition effect of interferon.

The invention relates to a preparation method of an organic hybrid trinuclear platinum complex possessing a Y type structure synthesized by supermolecules self-assembly as well as treatment for gastric adenocarcinoma cells. The MTT experiment data shows that the compound can cross a drug resistance mechanism of cisplatin, and can specifically target to the gastric adenocarcinoma cells. A platinum ligand Pt(NH3)2Cl(NO3)] in which the chloride ion is replaced by nitrate and a bridge ligand (2,4,6-tri(pyridin-4-yl)-1,3,5-triazine) are subjected to self-assembly, thereby the novel and latent medicine for treating gastric adenocarcinoma with excellent anticancer activity and tumor targeting is obtained. Because the complex enables specific recognition of the gastric adenocarcinoma cells, and can induce the G-rich sequence of the oncogene to form a G-quadruplex structure, the activity of telomerase can be inhibited, thereby the complex possesses high gastric adenocarcinoma resistance activity. The preparation method has the advantages of simple process and low cost, can be completed in a general chemical laboratory, and the production process is environmentally-friendly. The trinuclear platinum complex possessing Y type structure can be taken as the novel and latent gastric adenocarcinoma resistance medicine.

The invention discloses a preparation method of an alpha-glucan antigen and a specificity monoclonal antibody. The preparation method of the antigen comprises the following steps: mixing alpha-glucan and protein; dissolving with water; regulating the pH of solution to 5-8; carrying out freeze drying, and grinding into powder; putting the powder in the environment with constant temperature of 50-60DEG C and relative humidity of 60-90%; reacting for at least three days to obtain the alpha-glucan antigen. The preparation method of the antibody comprises the following steps: mixing the prepared antigen with an adjuvant, emulsifying the mixture, and injecting the emulsified mixture into animal bodies; blending the splenocyte and oncocyte of the animal body with the high serum valence to obtain a hybridoma cell capable of secreting the antibody; and producing the antibody by the hybridoma cell or with an ascites method. The antibody prepared by the method has high immunogenicity, and can be used for effectively inducing to generate immune response to obtain the antibody with the excellent property. The antibody obtained by the method provided by the invention can be subjected to specificity reaction with the alpha-glucan to generate macroscopic precipitates, and the antibody has high valence and can be used for the quantitative analysis on the alpha-glucan.

In an effort to discover therapies for treating HSP70 related diseases, a previously unidentified hydrophobic pocket was found in the C-terminal domain of DnaK and of human HSP70. A novel chemical scaffold was also discovered for identifying compounds that treat diseases related to this hydrophobic pocket. The compounds have the structure of the formula (I), wherein L, M, and R1-R5 are defined herein and are, therefore, in these therapies, optionally with other pharmaceutical agents such as genotoxic agents. Accordingly these compounds are useful in inhibiting HSP70 or DnaK, reducing HSP70 in mitochondria of a cancer cell, treating malignant neoplastic disease, or inhibiting or reducing bacterial growth. These compounds also resulted in novel methods of screening for a HSP70 inhibitor or DnaK inhibitor by using the three-dimensional structure of the hydrophobic pocket in DnaK or HSP70.

Relating to the field of gene therapy, the invention provides a method for knockout of a high-risk human papillomavirus (HPV) E6E7 gene by zinc finger nucleases (ZFNs). According to a high-risk type HPV E6E7 gene sequence, the method designs ZFNs expression vectors of a targeted specific site to targetedly cut the HPVE6E7 gene sequence in cells, thereby knocking out a target gene. In corresponding subtype HPV infected cells, the ZFNs can significantly induce cell apoptosis and proliferation inhibition, and has no effect on other subtype HPV positive cells and HPV negative cells. Transfection of the ZFNs expression vectors in a subcutaneous tumor model of HPV positive cervical cancer cells can obviously inhibit the growth rate of subcutaneous tumors and alleviate tumors. The method for targeted knockout of the high-risk HPV E6E7 gene by ZFNs can efficiently destroy virus oncogenes at the DNA level so as to make HPV infected cells undergo apoptosis and proliferation inhibition, and has enormous treatment value to HPV infection related diseases, especially cervical intraepithelial neoplasias and other precancerous lesions.

The invention discloses a novel peptide deformylase inhibitor containing spiro-three-membered ring and spiro-five-membered ring types. The novel peptide deformylase inhibitor containing the spiro-three-membered ring and spiro-five-membered ring types has antibacterial activity and anti-tumor activity. The peptide deformylase inhibitor containing the spiro-three-membered ring and spiro-five-membered ring types can serve as a novel antibacterial agent, by inhibiting the activity of peptide deformylase needed in synthesis of bacterium proteins, the novel peptide deformylase inhibitor is effective on multiple antibiotic resistant Gram-positive bacterium strains, the synthesis process of proteins of human bodies is not affected, and accordingly bacteria are killed selectively. The peptide deformylase inhibitor containing the spiro-three-membered ring and spiro-five-membered ring types can further serve as a novel anti-cancer drug; by inhibiting peptide deformylase in mitochondria of cancer cells, energy balance of the cells can be affected, accordingly mitochondrial membranes are depolarized, ATP is used up, and cell apoptosis is promoted; and the novel peptide deformylase inhibitor has good inhibiting activity to multiple cancer cell bacterial strains such as colorectal cancer cell bacterial strains, lung cancer cell bacterial strains, gastric cancer cell bacterial strains and liver cancer cell bacterial strains at the low concentration.

The invention relates to a SEA mutant gene and use for fusion protein thereof with ScFv gene, wherein gene engineering means is employed for saltation of super antigen SEA gene, which has the base sequence represented by the sequence table 1, by fusing it with anti-melanoma single-chain antibody (ScFv) gene obtained through bacteriophage displaying technique, a ScFv-SEA recombination antibody is constructed, wherein in vitro cell experiment proves that the fusion protein has inhibitory action to melanin oncocyte superior to other tumor, the fusion protein has evident targeting killing effect to melanin oncocyte.

The invention discloses a polypeptide chip of monoclonal antibody group screening with different antigen epitopes, which comprises the following steps: 1. synthesizing polypeptide according to the screened antigen of monoclonal antibody group; preparing polypeptide chip; 2. mixing the cell suspension of immune mouse spleen with the antigen and myeloid oncocyte at certain proportion; fusing two cell through fluxing agent to generate hybrid oncocyte; 3. collecting the hybrid oncocyte; cultivating for 7-8 days; making suspending liquid; 4. adapting polypeptide chip of different antigen epitopes to screen and identify the suspending liquid of hybrid oncocyte; 5. establishing a group of monoclonal antibody cell plant of different antigen epitopes with the positive clone screened and identified by polypeptide chip; 6. generating monoclonal antibody group of different antigen epitopes through cultivation enlargement and purity segregation.

It is an object of the present invention to provide a novel method for decreasing the number of clinical cases for which trastuzumab administration is ineffective. The present invention provides a method for treating a living individual with epithelial cancer comprising:step (a) of selectively reducing KLRG1-positive immunocytes in the peripheral blood of a living individual with epithelial cancer ex vivo, which is positive for a cancer-specific membrane antigen expressed in epithelial cancer cells and positive for a KLRG1 ligand; andstep (b) of administering, to the living individual, a therapeutic agent for cancer comprising an antibody reacting with the cancer-specific membrane antigen expressed in epithelial cancer cells and having antibody-dependent cell cytotoxicity.

The invention provides an application of Walker-256 cell strains in establishing a bone tumor pain model, in particular to an application of the Walker-256 cell strains in establishing a large rat bone tumor pain model. The application of the Walker-256 cell strains of the invention has successfully established the large rat bone tumor pain model. The establishment of the tumor pain model provides a useful tool for research of topics relating to bone tumor pain and particularly filtration of tumor pain resistant traditional Chinese medicines and compounds of the tumor pain resistant traditional Chinese medicines; moreover, the cell strains are derived from large rat primary breast carcinoma tissues, thereby the bone tumor pain model established by application of oncocyte can be regarded as a breast carcinoma transition model, and the invention has significant scientific research value and application prospect.

The present invention discloses one kind of grafted nanometer carbon suspension consisting of grafted nanometer carbon grain, physiological saline and pH regulator and its preparation process. The grafted nanometer carbon suspension may be used as lymph tracing medicine, which is injected in body of human or animal to enter the draining lymph node fast and to dye the lymph node into black or grey. The grafted nanometer carbon suspension may be also used as lymph targeting medicine, which is injected into the malignant tumor to reach the draining lymph node fast in the malignant tumor and to kill the metastic cancer cell inside lymph node directly.

Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.

The invention relates to an animal influenza target drug and relative production. Wherein, it uses single colon antibody to select the cross oncocyte seed which can resist animal influenza virus and inflammatory facto, and it can extract different cross oncocytes, via RT-PCT to obtain heavy chain variable area and light chain variable area genes with single antibody; and via SOE-PCT, to connect the VH, VL genes with one short peptide with 15 amino acid, to build the single chain antibody gene of single chain antibody gene, or single chain dual special antibody gene, and inflammatory facto, and connect the single chain antibody gene or single chain dual special antibody gene, via enzyme cutting to connect the single chain antibody gene or bacillus pyocyaneus ectotoxin PE40 gene of inflammatory facto, to build original core represent carrier, transfer Ecoli.BL21 projective virus, then via ferment, extraction, and purification, to obtain target antagonist.

The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5′-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3′, and preferably of the general formula 5′-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3′, wherein capital letters designate an LNA nucleotide analogue selected from β-D-oxy-LNA, β-D-thio-LNA, β-D-amino-LNA and α-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumor development in vivo. The LNA oligonucleotides are superior to other LNA oligonucleotides targeting Surviving mRNA measured by functional read outs such as apoptosis induction and proliferation inhibition, and is potent in down-regulating Survivin mRNA and protein in transfected cancer cell lines, and induce apoptosis in combination with Taxol superior compared to other LNA oligonucleotides.

The present invention is directed to methods of inhibiting cancer cell proliferation, differentiation and / or survival. These methods involve the administration of Fbw7 E3 ligase inhibitors to inhibit c-Myc ubiquitination in cancerous cell populations, such as leukemic initiating cell populations, that are responsible for disease initiation and progression.

There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 96) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and β-Ala, Amc, Apa, Ada, AE2A, AE4P, ε-Lys(α-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.

The invention discloses a LRP16 single cloned antibody hybrid tumor cell line CGMCC 1992 and the application of the cell line, and pertains to the technical field of medicine biology. The advantages with the invention are: 1) the chromosome is steady, and the cell line will secrete IgG1 antibody; 2) the cell line can be cultured in a no-serum culturing system; 3) the titer of the secreted antibody is high, the upper serum directly cultured can be up to 1:200,000; 4) abdominal dropsy of rat can be up to 1 mg / ml; the titer can be up to 1: 3,600,000, and can be purified by protein G; 5) the secreted antibody can be used for immunity combination (1:1000) and immunity mark (western blot) test (1:3000).

The invention discloses an application of an oncogenic kinase marker for liver cancer diagnosis and treatment, and discloses an application of oncogenic kinase STK39 in liver cancer diagnosis and treatment. The expression difference of the STK39 in normal liver tissues and liver cancer tissues is found for the first time, the expression quantity of the STK39 in the liver cancer tissues is obviously higher than that in the normal tissues, and a patient with high expression of the STK39 has poor prognosis, so that the STK39 is prompted to be closely related to occurrence, development and prognosis of the liver cancer. Knockdown, knockout and inhibition of STK39 can obviously inhibit the growth and invasion of hepatoma carcinoma cells, and it is indicated that STK39 can be used as a new target for diagnosis and treatment of hepatoma carcinoma. A kit and the technology for checking STK39 expression can be applied to liver cancer diagnosis and prognosis prediction, and treatment strategiessuch as antibodies or small molecule inhibitors of targeted oncokinase STK39 are expected to be applied to liver cancer treatment.

The invention discloses biomedical application of 1-deoxy-2,3-dehydronagilactone A serving as a UCP2 inhibitor for treating gastric adenocarcinoma. Nagilactone J, 1-deoxy-2,3-dehydronagilactone A, lamiophlomiol A and lamiophlomiol B serve as effective UCP2 inhibitors, and the nagilactone J, 1-deoxy-2,3-dehydronagilactone A, lamiophlomiol A and lamiophlomiol B can be further used for treating the gastric adenocarcinoma by inhibiting the UCP2 to inhibit proliferation of gastric adenocarcinoma cells.

The invention relates to sophora flavescens polysaccharide as well as a preparation method thereof and use thereof in liver protection and immune regulation. The sophora flavescens polysaccharide is extracted from sophora flavescens root in a way of water extraction. A polysaccharide component in the sophora flavescens polysaccharide is obtained by means of further separation. Experiments prove that the sophora flavescens polysaccharide and the polysaccharide component thereof can promote mouse spleen cell proliferation and cytokine secretion, promote human hepatocyte proliferation and reducethe damage of chemical agents to cells, inhibit the expression of hepatitis B surface antigen and core antigen, inhibit the proliferation of hepatocarcinoma cells and inhibit the damage, caused by ConA, to the liver and kidney of a mouse, thus being used for preparing immunomodulatory, anti-tumor and anti-hepatic injury drugs.

The invention relates to pediococcus acidilactici with an anti-cervical cancer effect. The name of the pediococcus acidilactici is HAO2018; the classification name is Pediococcus acidilactici; the preservation number is CGMCC No.16658, the preservation date is October 30, No. 3, Yard 1, West Beichen Road, Chaoyang District, Beijing, and the preservation unit is China General Microbiological Culture Collection Center. The pediococcus acidilactici can inhibit proliferation of cervical cancer HeLa cells, cause apoptosis of the HeLa cells, inhibit expression of human papilloma virus HPVE6 and E7 proteins and inhibit acetylation modification of histone in Hela cells. The Pediococcus acidilactici has good cervical cancer cell inhibition performance, is used for preparing a cervical cancer inhibition fermentation product and has a very wide application prospect.

The invention discloses a medicine for treating lung cancer. The medicine is composed of NG25 and trametinib at a mass ratio of 4 to 1; and the lung cancer is a lung cancer in which the function of CLU genes is absent or down-regulated. Further, the lung cancer is a lung cancer in which the function of the CLU genes is absent or down-regulated and is driven by KRASG 12D oncogenes. In vitro experiments show that CLU knock-down lung cancer cells are more sensitive to NG25, compared with controls, the NG25 can significantly inhibit the growth of the lung cancer cells, and while after the cells are treated by combining with the Trametinib, it is found that the inhibition on the lung cancer cells is even more significant. Similarly, in animal models, a TAK1 inhibitor NG25 can inhibit the growthof CLU knock-down cell transplantation tumors and CLU knock-out orthotopic lung cancer, the treatment combined with the Trametinib can significantly shrink the tumor, and the purpose of treating thetype of the lung cancer is achieved.

The present invention describes new compounds that are useful for image-guided surgery and photodynamic therapy. In particular the compounds may be targeted to the nucleus or the mitochondria after compounds were delivered to diseased tissues such as cancer using a ligand that target receptor that express on the diseased tissue and followed by receptor mediated endocytosis and provide effective activity against cancer cells as well as other disorders. Methods and compositions for use of the same are described.